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Abstract
Background: Vitamin D is well known for its function in calcium homeostasis and bone mineralisation, but is
increasingly studied for its potential immunomodulatory properties. Vitamin D deficiency is a common problem in
patients with COPD. Previous studies have not demonstrated a beneficial effect of vitamin D on exacerbation rate
in COPD patients. However, subgroup analyses suggested protective effects in vitamin D deficient patients. Our
objective is to assess the effect of vitamin D supplementation on exacerbation rate specifically in vitamin D
deficient COPD patients.
Methods/Design: We will perform a randomised, multi-center, double-blind, placebo-controlled intervention study.
The study population consists of 240 COPD patients aged 40 years and older with vitamin D deficiency
(25-hydroxyvitamin D concentration < 50 nmol/L). Participants will be recruited after an exacerbation and will
be randomly allocated in a 1:1 ratio to receive vitamin D3 16800 IU or placebo orally once a week during
1 year. Participants will receive a diary card to register the incidence of exacerbations and changes in
medication during the study period. Visits will be performed at baseline, at 6 months and at 12 months after
randomisation. Participants will undergo spirometry, measurement of total lung capacity and assessment of maximal
respiratory mouth pressure. Several physical performance and hand grip strength tests will be performed,
questionnaires on quality of life and physical activity will be filled in, a nasal secretion sample and swab will be
obtained and blood samples will be taken. The primary outcome will be exacerbation rate.
Discussion: This study will be the first RCT aimed at the effects of vitamin D supplementation on exacerbation rate in
vitamin D deficient COPD patients. Also, in contrast to earlier studies that used infrequent dosing regimens, our trial
will study effects of a weekly dose of vitamin D supplementation. Secondly, the immunomodulatory effects of vitamin
D on host immune response of COPD patients and underlying mechanisms will be studied. Finally, the effects on
physical functioning will be examined.
Trial registration: This trial is registered in ClinicalTrials.gov, ID number NCT02122627. Date of Registration April 2014.
Keywords: Chronic obstructive pulmonary disease, Exacerbation, Vitamin D, Immunomodulation, Physical function,
Randomised controlled trial
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Introduction
Chronic obstructive pulmonary disease (COPD) is char-
acterized by a persistent airflow limitation and an abnor-
mal inflammatory response of the airways. COPD is
predicted to be the third worldwide cause of mortality
by 2020 [1]. Exacerbations in COPD determine disease-
associated morbidity and mortality [2]. Patients with fre-
quent exacerbations have a more rapid decline in lung
function, worse quality of life and decreased exercise
performance. Yet, effective treatment alternatives to pre-
vent exacerbations are still lacking.
Vitamin D deficiency is highly prevalent in patients
with COPD [3, 4]. Traditionally, vitamin D is associated
with bone health. The discovery of the presence of vita-
min D receptors (VDR) in many other cells, such as
monocytes, macrophages, muscle cells and endothelial
cells, has elicited hypotheses of direct vitamin D effects
on these cells. These hypotheses are further strength-
ened by local 25-hydroxyvitamin D-1-alpha-hydroxylase
activity, which converts the inactive 25-hydroxyvitamin
D (25(OH)D) to the active 1,25-dihydroxyvitamin D
(1,25(OH)2D), in many of these cells. The presence of
vitamin D receptors on immune cells [5] and the high
prevalence of vitamin D deficiency among COPD pa-
tients has given rise to the hypothesis that vitamin D
might have a potential effect in preventing exacerbations
in patients with COPD [6].
Vitamin D and the immune system
There is a large body of evidence being generated in vitro
and in vivo to demonstrate that vitamin D influences the
innate and adaptive immune system. 1,25(OH)2D is the
active form of vitamin D that binds to the VDR, thereby
influencing the expression of more than 200 genes. VDR
is expressed on a range of immune cells such as macro-
phages, dendritic cells, and CD4-positive T lymphocytes
[5]. In the innate immune system vitamin D modulates
Toll-like receptor (TLR)-induced immune responses
through inhibition of the NF-κB-pathway and appears to
improve antimicrobial defences in general [7, 8]. Vitamin
D is capable of inducing endogenous expression of the
antimicrobial peptides (AMP) such as cathelicidin. This
has been reported in monocytes, macrophages, kerati-
nocytes and in lung epithelial cells [9, 10]. Because
AMPs have been found in multiple experimental sys-
tems to be essential for defence against a variety of mi-
crobial infections, it has been hypothesised that vitamin
D can enhance resistance to infections [11]. In addition,
vitamin D seems capable of modifying the function of
cells classically associated with adaptive immunity
whereby activation of VDR downregulates autoimmun-
ity by promoting the differentiation of T-cells into
regulatory T-cells [12].
Vitamin D and pulmonary infections
Vitamin D might influence the development and course
of tuberculosis. Patients with low 25(OH)D concentra-
tions have a higher risk of active tuberculosis and vita-
min D supplementation may shorten the duration of
disease [13]. It is also known that patients with rickets
more frequently suffer from airway infections and pneu-
monia [14]. Several prospective cohort studies in the gen-
eral population show that lower levels of 25(OH)D are
related to increased risk of respiratory infections [15, 16].
A trial with Japanese schoolchildren during the influenza
season demonstrated that, compared to placebo, vitamin
D supplementation lowered the incidence of influenza A
infections [17]. Trials assessing effects of vitamin D sup-
plementation on prevention of respiratory infections in
the general adult population have shown conflicting re-
sults, which may partly be attributed to differences in
prevalence of vitamin D deficiency at baseline and rise of
serum 25(OH)D levels during treatments [18, 19].
Vitamin D and COPD
Patients with COPD are characterised by an abnormal
inflammatory response of the airways. Viral and bacter-
ial infections are important triggers of exacerbations
and contribute to its progression. Thus, potential ef-
fects of vitamin D on the immune system pose an at-
tractive mechanism for the treatment of COPD. Also,
in some [20, 21], but not all [22] studies in the general
population serum 25(OH)D is positively associated with
lung function. Vitamin D deficiency is present in 40–80 %
of patients with COPD and is related to disease severity
[3, 4]. Recent cohort studies, however, did not show a rela-
tionship between 25(OH)D levels and exacerbation rate
[23, 24], although these studies had limited statistical
power to rule out effects of vitamin D deficiency.
In addition to exacerbations and lung function, skeletal
muscle dysfunction in COPD patients contributes to
poor exercise capacity, decreased quality of life and in-
creased mortality [25, 26]. In COPD patients, vitamin D
deficiency is related to impaired physical performance
[27]. In healthy adults, positive effects of vitamin D sup-
plementation have been demonstrated on muscle func-
tion and physical performance in particular in older and
frail individuals [28, 29].
RCTs vitamin D supplementation in COPD
Few studies have been performed on the effects of vita-
min D supplementation in patients with COPD. In the
trial performed by Lehouck et al. [30] vitamin D sup-
plementation did not reduce the incidence of exacerba-
tions. However, in a post-hoc analysis of a subgroup of
severely vitamin D deficient patients (25(OH)D concentra-
tion < 25 nmol/L), vitamin D supplementation decreased
the exacerbation rate. In a very recent multi-center trial by
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Martineau et al. [31] vitamin D protected against moder-
ate to severe exacerbations in a pre-specified subgroup of
vitamin D deficient (25(OH)D concentrations < 50 nmol/
L) participants, but not in the study population as a whole.
Two studies have been performed assessing the effect
of vitamin D supplementation on physical performance
in patients with COPD. A pilot RCT did not show ef-
fects of vitamin D supplementation on physical perform-
ance, but was limited by the small number of 36
participants and short follow-up of 6 weeks [32]. Also,
the study was not specifically aimed at patients with
vitamin D deficiency. In the aforementioned RCT by
Lehouck et al. a post-hoc subgroup analysis of 50 partic-
ipants following a rehabilitation programme during the
trial was performed [33]. Participants receiving vitamin
D supplementation had significantly larger improve-
ments in inspiratory muscle strength and peak exercise
tolerance, but not in quadriceps strength and 6-min
walking distance. However, this study had limited statis-
tical power and is only applicable for patients following
a rehabilitation programme. These findings justify a
well-designed RCT to study effects of vitamin D supple-
mentation on muscle strength and physical performance.
Little is known about the total dose and dose interval
needed for extra-skeletal effects of vitamin D. In the
study of Lehouck et al. [30] participants received a
monthly dose of 100.000 IU. In the study of Martineau
et al. [31] participants received 120.000 IU every two
months. A large dose interval improves compliance but
might also cause fluctuating levels of vitamin D metabo-
lites [34]. In two RCTs assessing the effect of vitamin D
supplementation on falls and fractures, an increase of
fall and/or fracture incidence were shown using annual
high dose supplementation [35, 36]. While the mechan-
ism by which vitamin D might cause an increase in falls
remains uncertain, several authors suggest it is the dosing
interval rather than the total dose that determined these
outcomes [37]. These results emphasize the need for an
RCT studying a more frequent dosing regimen of vitamin D.
In the present study we aim to study the effects of
vitamin D supplementation on exacerbation rate in COPD
patients with vitamin D deficiency. In addition, we will
also assess the effects of vitamin D on several measures of
physical performance. In our trial, we will administer a
weekly dosing regimen in contrast to earlier studies, which
used larger dosing intervals.
Methods
Study design and participants
The study is designed as a randomised double-blind,
multi-center, placebo-controlled trial, with an interven-
tion (n = 120) and a control group (n = 120). The study
population consists of COPD patients with GOLD stages
II-IV. Participants will be included if they have a vitamin
D deficiency (25(OH)D concentrations <50 nmol/L) and
a recent exacerbation of COPD. The eligibility criteria
are described in Table 1. Participants will be recruited if
they present with an exacerbation of COPD at the out-
patient clinic or emergency ward. Screening serum
25(OH)D concentration will be measured during the ex-
acerbation period. Inclusion and randomisation will take
place 6–8 weeks after recruitment or at a later time
point as soon as the participant has recovered. An ex-
acerbation is defined as sustained worsening of respira-
tory symptoms during 48 h requiring oral corticosteroid,
antibiotic or combination treatment that was initiated by
a physician [38]. Convalescence is defined as recovery to
the stable state. The recruitment will start in three aca-
demic hospitals and five peripheral hospitals in the sur-
roundings of the academic centers. Study visits will be
performed at baseline (t = 0), 6 months (t = 6) and
12 months (t = 12) after randomisation as depicted in
Fig. 1. Participants will be contacted by telephone at 2,
4, 8 and 10 months The study is approved by the Med-
ical Ethics Committee of the VU University Medical
Center, Radboud University Medical Center and Leiden
University Medical Center. Written informed consent
will be obtained from all participants.
Intervention
The participants will receive either vitamin D 16800 IU
(3 tablets of 5600 IU) or a matching placebo (3 placebo
tablets) orally once a week during 12 months in accord-
ance with the randomisation. The study medication will
be prepared under supervision of the clinical pharmacy
of the VU University Medical Center. Participants will
be asked to return the study medication that is left over
and these tablets will be counted as a measure for com-
pliance. Participants are allowed to use a maximum of
400 IU vitamin D a day during the study, as this is the
recommended daily intake by the Dutch Health Council.
Participants will be asked about their usual intake of
dairy products. Participants are advised (according to the
advice of the Dutch Health Council) to increase their in-
take to a level corresponding with 1000 mg calcium per
day. If this is not feasible, it will be advised to use calcium
supplements to a total calcium intake of 1000 mg/day dur-
ing the study.
Randomisation and masking
For treatment allocation in this trial, we will apply the
sequential balancing method with study center as the
first step in the balancing algorithm, followed by gen-
der, age and current smoking. These variables are (po-
tential) prognostic factors and thus should be balanced
over the treatment arms. Pharmacists of the VU Uni-
versity Medical Center, who are independent from the
clinical research team, will randomly assign participants by
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using a computer-generated randomisation list and will pre-
pare the study medication. After the last participant finishes
the trial masking will continue until after the data analyses.
Outcomes
Primary outcome
Exacerbation rate
Primary outcome is exacerbation rate. An exacerbation is
defined as sustained worsening of respiratory symptoms
during 48 h requiring oral corticosteroid, antibiotic or
combination treatment that was initiated by a phys-
ician. Respiratory symptoms include at least one of the
Anthonisen criteria, which are increased dyspnoea, spu-
tum volume or sputum purulence, with or without
minor symptoms such as cough, fever, common cold,
wheezing or sore throat [38]. Participants will register
symptoms and changes in medication on a diary card
during the whole study period. During each telephone
Table 1 Eligibility criteria for the PRECOVID trial
Inclusion criteria Exclusion criteria
Vitamin D deficiency (serum 25(OH)D < 50 nmol/l) Severe vitamin D deficiency (serum 25(OH)D <15 nmol/l),
Postbronchodilator FEV1/FVC < 0.70, FEV1 < 80 % and
diagnosis COPD confirmed by a physician
Use of a supplement containing more than 400 IU vitamin D per day
Recent COPD exacerbation Use of maintenance dose oral corticosteroids
≥10 packyears of smoking Diagnosed asthma
Age≥ 40 years Diagnosed osteoporosis
Written informed consent Self-reported history of hypercalcaemia or nephrolithiasis
Ability to comply with all study requirements. Self-reported presence of sarcoidosis
Diagnosed chronic kidney disease stage 4 or higher (eGFR≤ 29 ml/min/1.73 m2)
Interfering malignant diseases
Life expectation of less than 1 year on the basis of concurrent disease
Current participation in a clinical rehabilitation program
Pregnant or lactating women, or subjects who intend to become
pregnant within the study period
Potentially unreliable patients and those judged by the investigator
to be unsuitable for the study
Serious mental impairment i.e. preventing to understand the study
protocol or comply with the study aim
25(OH)D 25-hydroxyvitamin D, FEV1 Forced Expiratory Volume in one second, FVC Forced Vital Capacity, eGFR estimated Glomerular Filtration Rate with the
MDRD formula
12 months
- blood sample
- nasal secretion
- lung function 
- MIP/MEP
- TLC
- physical 
function
- questionnaires
12 months 16800 IU vitamin D3 or placebo per week6-8 weeks
0 months
- blood sample
- nasal secretion
- lung function 
- MIP/MEP
- TLC
- physical  
function
- questionnaires
6 months
- physical 
function
- questionnaires
Registration of exacerbations and medication use
Screening and randomisation
2 & 4 months
telephone 
contact
8 & 10 months 
telephone 
contact
Recruitment
Fig. 1 Flowchart of study procedures during the PRECOVID trial. Randomisation will take place within 6-8 weeks after an exacerbation. During the
study period of one year three study visits and four telephone contacts will take place. MIP: Maximal inspiratory pressure; MEP: Maximal expiratory
pressure; TLC: Total lung capacity
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contact and study visit diary cards will be discussed and
reviewed. Also questions will be asked regarding
hospitalization during the last months. If necessary, in-
formation on changes in medication and COPD exacer-
bations during the study period will be confirmed
through contact with the providing pharmacist, the
general practitioner and hospital.
Secondary outcomes
Time to first and second exacerbation and time to fist
hospitalisation
Time to first and second exacerbation and time to first
hospitalisation will be registered on the basis of the diary
card and interviews.
Use of antibiotic and corticosteroids
With the use of earlier mentioned diary card and inter-
views the use of antibiotics and corticosteroids will be
registered.
Spirometry measures
At t = 0 and t = 12 participants will undergo spirometry.
The spirometry will be performed according to American
Thoracic Society/European Respiratory Society (ATS/
ERS) guidelines [39]. Only post-bronchodilator forced ex-
piratory volume in one second (FEV1) and forced vital
capacity (FVC) will be determined. Measurements will
take place after inhalation of the sympathomimetic
salbutamol and/or the anticholinergic ipratropium bromide.
Inspiratory capacity (IC) and expiratory reserve volume
(ERV) will also be determined according to ATS/ERS
guidelines [39].
Lung volumes
Measurements of absolute lung volume, residual volume
(RV), functional residual capacity (FRC) and total lung
capacity (TLC) will be assessed by body plethysmogra-
phy according to guidelines of the ATS/ERS task force at
t = 0 and t = 12 [40, 41].
Maximal respiratory mouth pressures
Respiratory muscle strength will be tested by measure-
ment of the maximal inspiratory and expiratory mouth
pressure (MIP and MEP, respectively). Measurement will
be made with a mechanical pressure gauge that is con-
nected to a mouthpiece according to the revised ATS
guideline [42].
Physical performance
During every visit (t = 0, t = 6 and t = 12), participants
will perform physical performance tests.
In the 6-min walking test the participant is asked to
walk as far as possible during a period of 6 min. The
participant will walk up and down a hallway. The 6-min
walking test is performed according to the ATS guide-
lines [43].
In the chair-stands-test the participant will be asked to
fold his arms across his chest and to stand up from a sit-
ting position and sit down five times as quickly as pos-
sible [44, 45].
In the 3-meter walking test the participant is asked
to walk three meters, turn around 180° and walk back
[44, 46].
In the tandem test the participant is asked to stand
with the heel of one foot directly in front of, and touch-
ing the toes of, the other foot for at least 20 s with his
eyes open and closed [44, 47].
Muscle strength
Muscle strength will be assessed with measurement of
hand grip strength. The participant is seated in a chair
and holds the dynamometer in the hand, with the arm at
right angles and the elbow by the side of the body. The
handle of the dynamometer is adjusted if required. When
ready, he squeezes the dynamometer with maximum iso-
metric effort, which is maintained for about 5 s. No other
body movement is allowed. This measurement will be per-
formed three times with both hands [48].
Quality of life
Quality of life will be assessed by three questionnaires
These will be completed at every study visit.
The St. George’s Respiratory Questionnaire (SGRQ) is
designed to measure health impairment in patients with
asthma and COPD [49, 50] and produces a symptoms
score and an activity and impacts score.
The Short Form 12 health Survey (SF-12) is a multi-
purpose short-form generic measure of health status
[51]. It is a validated subset of the larger SF-36 and
monitors health in general and in specific populations.
These scores correlate highly with the SF-36 versions
[52]. The SF-12 has been previously used in patients
with COPD [50, 53].
The Clinical COPD questionnaire (CCQ) is a simple
10-item, health-related quality of life questionnaire with
good psychometric properties [54]. The questionnaire is
responsive to pulmonary rehabilitation and a minimal clin-
ically important difference has recently been defined [55].
Anxiety and depression
Anxiety and depression will be assessed by means of two
questionnaires and will be completed at every study visit.
The Hospital Anxiety Depression Scale (HADS) is a ques-
tionnaire measuring feelings of depression and anxiety
[56]. Reliability and validation of the Dutch translation of
the HADS has been reported [57]. The HADS is frequently
applied in research in patients with COPD [58, 59].
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The Center for Epidemiologic Studies Depression
Scale (CES-D) is a self-report scale designed to measure
depressive symptoms in the general population. The de-
velopment of the scale has been described in detail else-
where [60]. The scale has been used in several COPD
populations [61, 62].
Physical activity
Physical activity will be assessed by the Short QUes-
tionnaire to ASses Health enhancing physical activity
(SQUASH). SQUASH is a self-report instrument to
measure habitual physical activity [63]. The question-
naire has been used in COPD populations [64].
Antimicrobial peptides and pro-inflammatory mediators in
nasal secretions
Nasal secretions will be collected by vacuum-aided
suction to prevent dilution that occurs when using
lavage-based methods [65]. The nasal secretions will
be analysed for the presence of antimicrobial peptides
and pro-inflammatory cytokines (hCAP18/LL-37, HNP1-
3, NGAL, IL-1ß, TNF-α, IL-6) using enzyme-linked im-
munosorbent assays (ELISA).
Typing of bacteria and viruses in nasal secretions
A nasal swab will be obtained using standard proce-
dures. PCR on presence of bacteria and respiratory vi-
ruses (non-typeable Haemophilus influenzae, Streptococcus
pneumoniae, Moraxella catarrhalis and a panel of respira-
tory viruses including rhinovirus) will be performed.
Inflammation and host response against infectious agents
In one of the academic centers peripheral blood mono-
nuclear cells (PBMC) and platelets will be derived from
50 participants before and after the intervention. Venous
blood will be drawn in EDTA and 3.2 % sodium citrate
tubes after which PBMC and platelet-rich plasma (PRP)
will be isolated, washed and suspended. PBMC will be
stimulated with various agonists to TLR (bacterial, fun-
gal and viral) and with microbial stimuli. The following
stimuli will be used: RPMI (control), LPS (TLR4),
Pam3Cys (TLR2), Poly (I:C) (TLR 3), Streptococcus pneu-
moniae, Non-typeable Haemophilus influenza, Pseudo-
monas aeroginosa, Aspergillus fumigatus, sonicated
Mycobacterium avium and Candida albicans. Pro- and
anti-inflammatory cytokines will be measured before and
after stimulation: TNF-α, Il-1ß, IL-6, IFN-γ (24 h incuba-
tion) and IL-10, IL-17 and IL-22 (7 days incubation). All
cytokines will be measured in cell culture supernatants
using ELISA. PRP will be used for analyses of platelet
function in terms of activation and aggregation. Second,
phenotyping of circulating immune cells will be done
using advanced multiparameter flowcytometry and func-
tional readouts. A whole blood staining will be used to be
able to calculate absolute numbers of CD4 (including
Treg), CD8 T cells, NK cells, B cells and monocytes.
Next, a detailed phenotypic analysis of the T cell com-
partment will be performed by additional staining of
whole blood or isolated PBMC using antibodies. Func-
tional characteristics of the T cell compartment (CD4+,
CD8+, CD4+/Foxp3+ (Treg)) with respect to cytokine
production (IFN-γ, IL-2, IL-4, IL-5, IL-10 and IL-17A)
and their associated transcription factors (Tbet, Gata-3,
RORyt) will be analysed.
Sample size calculation
The study is designed to demonstrate a minimum differ-
ence of one exacerbation per patient-year between the
vitamin D and the placebo group. We based our as-
sumptions on post-hoc analyses of the RCT by Lehouck
et al.[30], which had a similar patient sample, although
without selection for vitamin D deficiency. Based on dif-
ferences in Poisson means, a sample size of 94 partici-
pants per group is needed to demonstrate a difference of
1 exacerbation per patient-year with 80 % power at 5 %
significance. This number was based on the assumption
of 2.45 exacerbations per patient-year in the intervention
group and 3.45 in the placebo group. To account for a
dropout rate of 20 % 120 participants will be recruited
per study group.
Statistical analysis
Primary outcome
The primary outcome of the trial, exacerbation rate, will
be analysed with generalized linear models for a Poisson
distribution. Analyses will be adjusted for the variables
included in the balancing algorithm for randomisation,
i.e. study center, gender, age and current smoking. The
outcomes will be presented as rate ratios with their 95 %
confidence interval.
Secondary outcomes
Time to first exacerbation and hospitalisation will be
assessed with Kaplan–Meier curves and Cox propor-
tional hazard models. Dichotomous secondary out-
comes will be analysed with logistic regression models
and continuous secondary outcomes with analysis of
covariance. All analyses will be adjusted for the variables
included in the balancing algorithm for randomisation,
i.e. study center, gender, age and current smoking.
Because of the exploratory nature of the analyses, no
correction will be made for the multiple analyses. All
analyses of the trial will use the intention-to-treat popu-
lation, defined as all randomly assigned participants
who received at least 1 dose of study medication. A per-
protocol analysis will be performed on those partici-
pants with a good compliance i.e. obtaining a serum
25(OH)D concentration above the 20th percentile after
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12 months. Also, a subgroup analysis will be performed
in participants with a baseline serum 25(OH)D concen-
tration of 25 nmol/L or less.
Discussion
This RCT is the first intervention study examining effects
of vitamin D supplementation in a cohort of vitamin D
deficient COPD patients. With this study we expect to
gain more insight in the effects of vitamin D supplementa-
tion on exacerbation rate and both pulmonary and phys-
ical function. The two previous RCTs [30, 31] did not
show an effect of vitamin D supplementation in the total
study population of COPD patients. They did, however,
show a protective role of vitamin D against exacerbations
in deficient patients. These are promising results and
emphasise the need for an RCT specifically in vitamin
D deficient patients considering the high prevalence of
vitamin D deficiency in patients with COPD. In our
study participants with a severe vitamin D deficiency
(25(OH)D <15 nmol/L) will be excluded because of eth-
ical considerations.
Our study differs in several other aspect from previous
studies. In addition to the effects of vitamin D on ex-
acerbation rate, present study will focus on potential
underlying mechanisms. In nasal secretion the presence
of antimicrobial peptides and pro-inflammatory media-
tors will be measured and the microbial composition of
the nasal mucosa will be analysed. Furthermore, PBMCs
from a subgroup of participants will be challenged with
TLR-ligands and several pathogens in order to measure
cytokine responses. These tests will be performed before
and after the intervention to measure effects ofvitamin
D supplementation on cytokine responses and therefore
inflammation and host respone. Finally we will assess
physical performance in several different manners.
In contrast to earlier studies, we will use a weekly dos-
ing regimen, which leads to more stable 25(OH)D levels
[34], but may influence compliance. This is important
since little is known about the total dose and dose inter-
val needed for extra-skeletal effects of vitamin D.
As stated earlier exacerbations have a major impact on
somatic and mental health status of COPD patients [2].
With the increasing prevalence of COPD, the economic
burden will expand significantly [1]. Exacerbations con-
stitute the most important direct costs associated with
COPD. Treatments directed to reduce incidence and se-
verity of exacerbations improve long-term health status
and reduce health care costs [66]. Vitamin D might
therefore be an attractive treatment alternative, as it is
easily applicable, cheap and safe.
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